Key Takeaways
- • Synthego, a Redwood City-based CRISPR toolmaker, closed a $110 million Series C funding round led by Peter Thiel's Founders Fund, bringing total capital raised to $160 million.
- • The financing will accelerate Synthego's expansion of its CRISPR product lines and enable broader commercialization of gene-editing capabilities across research and molecular diagnostics applications.
- • Founders Fund's lead investment signals institutional venture capital confidence in synthetic biology and genome engineering as a viable, scalable commercial market.
- • Synthego specializes in providing scientists with tools, expertise, and support for synthetic biology and genome engineering, with expanded focus on molecular and clinical diagnostic reagents.
Summary
Synthego announced the close of a $110 million Series C funding round on Tuesday, led by Founders Fund, the venture capital firm founded by Peter Thiel. The Redwood City, California-based biotechnology company disclosed that the new capital brings its total funding to $160 million, representing a significant capital infusion to support expansion of its CRISPR gene-editing platform.
The company specializes in synthetic biology and genome engineering, providing scientists with tools and expertise to accelerate scientific discovery. Synthego has positioned itself as a critical infrastructure player in the CRISPR ecosystem, enabling downstream researchers and commercial entities to deploy gene-editing technology. The Series C proceeds will fund development of Synthego's two core gene-editing product lines while accelerating the company's mission to provide global access to CRISPR capabilities.
Founders Fund's decision to lead the round reflects growing institutional interest in the commercialization of CRISPR tooling and synthetic biology platforms. Rather than investing directly in therapeutic development, Founders Fund's participation highlights confidence in the business model of providing enabling technology to researchers and biopharma companies pursuing their own gene-editing programs. This reflects a broader venture capital thesis that the infrastructure layer of the CRISPR ecosystem—tools, reagents, and platforms—represents a durable, capital-efficient business opportunity.
Synthego's expansion into molecular and clinical diagnostic reagents signals the company's intent to broaden beyond pure research applications into higher-margin diagnostic and therapeutic support markets. This diversification strategy, coupled with substantial funding, positions Synthego to capture market share as CRISPR adoption accelerates across academia, contract research, and pharmaceutical development pipelines.
The company specializes in synthetic biology and genome engineering, providing scientists with tools and expertise to accelerate scientific discovery. Synthego has positioned itself as a critical infrastructure player in the CRISPR ecosystem, enabling downstream researchers and commercial entities to deploy gene-editing technology. The Series C proceeds will fund development of Synthego's two core gene-editing product lines while accelerating the company's mission to provide global access to CRISPR capabilities.
Founders Fund's decision to lead the round reflects growing institutional interest in the commercialization of CRISPR tooling and synthetic biology platforms. Rather than investing directly in therapeutic development, Founders Fund's participation highlights confidence in the business model of providing enabling technology to researchers and biopharma companies pursuing their own gene-editing programs. This reflects a broader venture capital thesis that the infrastructure layer of the CRISPR ecosystem—tools, reagents, and platforms—represents a durable, capital-efficient business opportunity.
Synthego's expansion into molecular and clinical diagnostic reagents signals the company's intent to broaden beyond pure research applications into higher-margin diagnostic and therapeutic support markets. This diversification strategy, coupled with substantial funding, positions Synthego to capture market share as CRISPR adoption accelerates across academia, contract research, and pharmaceutical development pipelines.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.